ROIC společnosti Starpharma
Jaká je hodnota metriky ROIC společnosti Starpharma?
Hodnota metriky ROIC společnosti Starpharma Holdings Limited je -26.55%
Jaká je definice metriky ROIC?
Return on invested capital (ROIC) is a financial ratio that measures how efficient a company is at allocating the capital under its control to profitable investments.
= NOPAT / Invested capital = EBIT * (1 - tax rate) / (2-year average liabilities + 2-year average shareholder equity)
Return on invested capital (ROIC) ratio gives investors a sense of how well a company is using money under its control to generate profitable returns.
ROIC can be used as a benchmark to calculate the valuation of companies across industries. A higher ROIC means the company is doing a better job of investing the money from shareholders and bondholders to run the business. A company is creating value if its ROIC exceeds 2%. If its ROIC is under 2%, the company is likely destroying value and has no excess capital to invest in future growth.
You can calculate ROIC with the following formula:
NOPAT = Net operating profit after tax
Invested Capital = Average total liabilities + Average shareholders' equity
The averages of liabilities and shareholders' equity are calculated as geometrical averages of the last two annual values from the company's balance sheet.
ROIC společností v sektoru Health Care sektor na ASX ve srovnání se společností Starpharma
Čemu se věnuje společnost Starpharma?
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Firmy s metrikou roic podobnou společnosti Starpharma
- Hodnota metriky ROIC společnosti Pacific Booker Minerals je -26.65%
- Hodnota metriky ROIC společnosti Serko je -26.65%
- Hodnota metriky ROIC společnosti Essa Pharma Inc je -26.63%
- Hodnota metriky ROIC společnosti Vir Biotechnology Inc je -26.61%
- Hodnota metriky ROIC společnosti Nano-X Imaging je -26.56%
- Hodnota metriky ROIC společnosti Fate Therapeutics Inc je -26.56%
- Hodnota metriky ROIC společnosti Starpharma je -26.55%
- Hodnota metriky ROIC společnosti Hi Crush Inc je -26.50%
- Hodnota metriky ROIC společnosti Dominion Water Reserves je -26.48%
- Hodnota metriky ROIC společnosti Ultimate Sports Plc je -26.48%
- Hodnota metriky ROIC společnosti Genfit SA je -26.47%
- Hodnota metriky ROIC společnosti Pmv Pharmaceuticals Inc je -26.40%
- Hodnota metriky ROIC společnosti Anaplan Inc je -26.36%